Last reviewed · How we verify

didanosine, ddI (drug)

French National Agency for Research on AIDS and Viral Hepatitis · Phase 3 active Small molecule

didanosine, ddI (drug) is a Nucleoside reverse transcriptase inhibitor (NRTI) Small molecule drug developed by French National Agency for Research on AIDS and Viral Hepatitis. It is currently in Phase 3 development for HIV-1 infection (as part of combination antiretroviral therapy).

Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating within host cells.

Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating within host cells. Used for HIV-1 infection (as part of combination antiretroviral therapy).

At a glance

Generic namedidanosine, ddI (drug)
SponsorFrench National Agency for Research on AIDS and Viral Hepatitis
Drug classNucleoside reverse transcriptase inhibitor (NRTI)
TargetHIV reverse transcriptase
ModalitySmall molecule
Therapeutic areaInfectious Disease / Virology
PhasePhase 3

Mechanism of action

Didanosine is a purine nucleoside analog that is phosphorylated intracellularly to its active form, dideoxyadenosine triphosphate (ddATP). This active metabolite competes with natural deoxyadenosine triphosphate for incorporation into the growing DNA chain during reverse transcription, causing chain termination and inhibiting HIV replication. It was one of the early antiretroviral agents used in HIV treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about didanosine, ddI (drug)

What is didanosine, ddI (drug)?

didanosine, ddI (drug) is a Nucleoside reverse transcriptase inhibitor (NRTI) drug developed by French National Agency for Research on AIDS and Viral Hepatitis, indicated for HIV-1 infection (as part of combination antiretroviral therapy).

How does didanosine, ddI (drug) work?

Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating within host cells.

What is didanosine, ddI (drug) used for?

didanosine, ddI (drug) is indicated for HIV-1 infection (as part of combination antiretroviral therapy).

Who makes didanosine, ddI (drug)?

didanosine, ddI (drug) is developed by French National Agency for Research on AIDS and Viral Hepatitis (see full French National Agency for Research on AIDS and Viral Hepatitis pipeline at /company/french-national-agency-for-research-on-aids-and-viral-hepatitis).

What drug class is didanosine, ddI (drug) in?

didanosine, ddI (drug) belongs to the Nucleoside reverse transcriptase inhibitor (NRTI) class. See all Nucleoside reverse transcriptase inhibitor (NRTI) drugs at /class/nucleoside-reverse-transcriptase-inhibitor-nrti.

What development phase is didanosine, ddI (drug) in?

didanosine, ddI (drug) is in Phase 3.

What are the side effects of didanosine, ddI (drug)?

Common side effects of didanosine, ddI (drug) include Pancreatitis, Peripheral neuropathy, Diarrhea, Nausea, Headache, Lactic acidosis.

What does didanosine, ddI (drug) target?

didanosine, ddI (drug) targets HIV reverse transcriptase and is a Nucleoside reverse transcriptase inhibitor (NRTI).

Related